Atty Dkt. No.: GLAD-281 USSN: 10/627,447

I. AMENDMENTS

AMENDMENTS TO THE CLAIMS

Cancel claim 5 without prejudice to renewal.

Please enter the amendments to claim 1, as shown below.

- 1. (**Currently amended**) A method for diagnosing Alzheimer's Disease (AD) in a living individual, the method comprising detecting a level of carboxyl-terminal truncated apolipoprotein E (apoE) in an aqueous biological sample from the individual, wherein the carboxyl-terminal truncated apoE comprises amino acids 244-260 of apoE, and wherein the carboxyl-terminal truncated apoE is a form such that a level of the carboxyl-terminal truncated apoE that is significantly higher than the level present in a normal control indicates that the individual has AD.
 - 2. (Original) The method of claim 1, wherein the biological sample is blood.
 - 3. (Original) The method of claim 1, wherein the biological sample is serum.
- 4. (Original) The method of claim 1, wherein the carboxyl-terminal truncated apoE has a molecular weight of about 14-20 kDa.
 - 5. (Cancelled)
 - 6. (Original) The method of claim 1, wherein apoE is apoE4.
 - 7. (Original) The method of claim 1, wherein apoE is apoE3.
 - 8. (Original) The method of claim 1, wherein apoE is a mixture of apoE3 and apoE4.
 - 9. (Canceled)
- 10. (Previously presented) The method of claim 1, further comprising detecting a level of full length apolipoprotein E (apoE) in the biological sample from the individual; wherein a ratio of the level of carboxylterminal truncated apoE compared to the level of full length apoE in the biological sample that is greater than a

Atty Dkt. No.: GLAD-281

USSN: 10/627,447

ratio associated with a control biological sample from an individual not having Alzheimer's Disease is indicative of a diagnosis of Alzheimer's Disease.

11. (Previously presented) The method of claim 10, wherein the carboxyl-terminal truncated apoE has a molecular weight of about 14-20 kDa.

- 12. (Previously presented) The method of claim 10, wherein a ratio of the level of carboxyl-terminal truncated apoE compared to the level of full length apoE in the biological sample that is at least 25% greater than a ratio associated with a control biological sample from an individual not having Alzheimer's Disease is indicative of a diagnosis of Alzheimer's Disease.
- 13. (Previously presented) The method of claim 10, wherein a ratio of the level of carboxyl-terminal truncated apoE compared to the level of full length apoE in the biological sample that is at least 50% greater than a ratio associated with a control biological sample from an individual not having Alzheimer's Disease is indicative of a diagnosis of Alzheimer's Disease.
- 14. (Previously presented) The method of claim 10, wherein a ratio of the level of carboxyl-terminal truncated apoE compared to the level of full length apoE in the biological sample that is at least 2-fold greater than a ratio associated with a control biological sample from an individual not having Alzheimer's Disease is indicative of a diagnosis of Alzheimer's Disease.
- 15. (Withdrawn) A kit for diagnosing Alzheimer's Disease, the kit comprising an antibody that binds to carboxyl-terminal truncated apolipoprotein E (apoE) and instructions for using the antibody for diagnosing Alzheimer's Disease.
 - 16. (Withdrawn) The kit of claim 15, further wherein the antibody is attached to a solid support.
- 17. (Withdrawn) The kit of claim 15, further comprising an antibody that specifically binds to a carboxyl-terminal portion of full-length apoE.
- 18. (Withdrawn) The kit of claim 15, wherein the instructions for the diagnosis of Alzheimer's Disease direct the use of the kit to detect carboxyl-terminal truncated apoE in serum.
 - 19. (Previously presented) The method of claim 1, wherein the biological sample is plasma.

Atty Dkt. No.: GLAD-281 USSN: 10/627,447

20. (Previously presented) The method of claim 1, wherein the biological sample is cerebrospinal fluid.

- 21. (Withdrawn) The kit of claim 17, wherein the antibody that specifically binds to a carboxylterminal portion of apoE binds specifically to an epitope within amino acids 270-299 of apoE.
 - 22. (Withdrawn) The kit of claim 16, wherein the solid support is a test strip.